Oruka Therapeutics (NASDAQ:ORKA) Announces Earnings Results, Beats Estimates By $0.04 EPS

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04, FiscalAI reports.

Oruka Therapeutics Price Performance

Shares of ORKA traded down $1.94 during trading hours on Friday, hitting $61.96. The stock had a trading volume of 885,048 shares, compared to its average volume of 1,034,307. The company’s fifty day moving average is $54.63 and its two-hundred day moving average is $39.18. Oruka Therapeutics has a 52 week low of $9.40 and a 52 week high of $91.00. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of -31.92 and a beta of -0.20.

Get Oruka Therapeutics alerts:

Insider Activity

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the transaction, the chief executive officer owned 927,309 shares in the company, valued at $38,297,861.70. This represents a 0.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31. Following the transaction, the insider owned 33,377 shares in the company, valued at approximately $1,365,453.07. This trade represents a 18.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 23,765 shares of company stock worth $1,089,745. 23.49% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. Legal & General Group Plc acquired a new position in Oruka Therapeutics during the 2nd quarter worth about $28,000. BNP Paribas Financial Markets lifted its position in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares in the last quarter. Royal Bank of Canada lifted its position in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Oruka Therapeutics during the 4th quarter worth about $37,000. Finally, PNC Financial Services Group Inc. acquired a new position in Oruka Therapeutics during the 3rd quarter worth about $39,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ORKA shares. Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the company a “buy” rating in a report on Monday, April 27th. BTIG Research reaffirmed a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Thursday. Stifel Nicolaus upped their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a report on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.80.

View Our Latest Analysis on ORKA

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

Featured Stories

• Five stocks we like better than Oruka Therapeutics
• Viking Sails to All-Time Highs—Fundamentals Signal More to Come
• Datavalut Gains Traction: 5 Reasons to Sell Now
• TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
• The Power Grid Is Dying—Is It Time to Buy Its Replacement?

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.